56 results about "Vasopressin" patented technology

The disclosed invention is a composition agonists and / or antagonists of V.sub.2, V.sub.1a or both receptors, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.

The invention describes compositions of peptide analogs exemplified by peptides derived from vasopressin, terlipressin, and GLP1 and others that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide, wherein A is a hydrophobic moiety or a metal binding moiety, and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. A may be linked to Cm by a linker group. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.

A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.

Novel compounds of Formula (I)and pharmaceutically acceptable salts thereof, and pharmaceutical formulations containing such compounds which are useful as anti-aquaretic agents in the treatment of nocturnal urinary enuresis, nocturnal urinary urgency, and / or similar conditions.

The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia, and so forth. Specifically, the invention provides azole derivatives represented by general formula (I), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (AVP) V1b receptor:

The present invention relates to high-throughput mammalian and medium-throughput oocyte-based electrophysiological assays for identifying human TRPML3 modulators, preferably TRPML3 enhancers. Compounds that modulate TRPML3 function in the assay are expected to affect salty taste in humans. The inventive electrophysiological assays, such as the two-electrode voltage-clamp technique, facilitate the identification of compounds which specifically modulate human TRPML3. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit TRPML3 function. Compounds that enhance or block TRPML3 channel activity should thereby modulate salty taste. In addition, these compounds may be used to regulate sodium excretion, urinary output and other biological functions relating to sodium levels. This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The inventors have identified TRPML3 as encoding a salty taste receptor in primates and humans (and likely other mammals) based on gene expression assays which have determined that TRPML3 is expressed specifically in taste bud cells and not in lingual epithelial cells, similar assays that have determined that TRPML3 is specifically expressed or enriched in the top half of taste bud cells in a subset of taste cells which do not express TRPM5 or PKD2L1, prior reports that document the expression of TRPML3 in other sensory organs such as the ear (therefore further substantiating the role of TRPML3 as a 'professional' sensory gene).

Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH2, O and N-alkyl, Z is either S or -CH=CH-, R<1 >and R<2 >are independently selected from H, F, Cl, Br and alkyl, R<3 >is selected from OH, O-alkyl and NR<4>R<5>, R<4 >and R<5 >are each independently H or alkyl, or together are -(CH2)q-, p is 0, 1, 2, 3 or 4, and q is 4 or 5, are new. They are agonists at the asopressin V2 receptor and are useful as antidiuretics and pro-coagulants.

The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.

The invention discloses extraction process of a vasopressin solution. The extraction process includes the steps of raw material extraction, protein removal, resin exchange, ultrafiltration, and purification through preparative high performance liquid chromatography. The process combines various separation and purification methods to directly separate and purify the vasopressin from pituitary of animals. The raw material is low in cost and is easy to obtain. The product is high in yield and purity. The process has simple operations, is environment-friendly, is short in production period and is low in production cost, and is suitable for large-scale industrial production.

The invention relates to bisulfamide compounds as well as a preparation method and use thereof, and specifically relates to bisulfamide compounds having the structure as shown in a formula I and pharmaceutically acceptable salts thereof as well as a preparation method of the bisulfamide compounds, pharmaceutical compositions with the bisulfamide compounds having the structure as shown in the formula I and the pharmaceutically acceptable salts thereof as active effective constituents and use of the pharmaceutical compositions in preventing or treating diseases associated with an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor, an arginine vasopressin V2 receptor, the sympathetic nervous system or the renin-angiotensin-aldosterone system; the formula I is as shown in the specification.

An object of the present invention is to provide a novel benzazepine compound or a salt thereof, which has excellent vasopressin antagonistic activity. The benzazepine compound or a salt thereof of the present invention is represented by Formula (1): wherein R 1 , R 2 and R 5 may be the same or different and each represents H or D; and R 3 and R 4 each represents a C 1-6 alkyl group, a C 1-6 deuteroalkyl group, or a C 1-6 perdeuteroalkyl group.

The invention relates to high-molecular-weight recombinant human kininogenase, and a preparation method and application thereof. Specifically, the invention relates to the high-molecular-weight recombinant human kininogenase prepared by using a mammal cell culture production method and specific purifying technology for the first time. According to results of SDS-PAGE electrophoresis determination, the molecular weight of the high-molecular-weight recombinant human kininogenase is 43 to 49 KDa; the high-molecular-weight recombinant human kininogenase is glycoprotein and contains three N-Link glycosylation binding sites which are respectively located at Asn78, Asn84 and Asn141; and compared with kininogenase originated from human urine, the high-molecular-weight recombinant human kininogenase has a more complicated and more complete glycosylation level and obviously reduces a deamidation level. The high-molecular-weight recombinant human kininogenase obtained in the invention can substantially prolong in-vivo half-life and reduce side effects. The invention also relates to application of the high-molecular-weight recombinant human kininogenase in treatment of kidney failure.

The invention discloses a method for refining impurities of vasopressin [5‑Asp]. The refining method of vasopressin [5-Asp] impurity comprises the steps of: adopting high performance liquid phase chromatography to carry out reverse-phase enrichment, reverse-phase salt conversion, reverse phase Phase purification can be done; the packing of high performance liquid phase chromatography is super water-resistant packing; reverse-phase enrichment, reverse-phase salt conversion, and reverse-phase purification are all completed in a one-step reverse-phase elution process. The purification method of the vasopressin [5‑Asp] impurity of the present invention produces mostly waste water in the purification process, which can be reused after simple treatment at a sewage station, and is economical and environmentally friendly.

The invention discloses a preparation method for vasopressin[4-Glu]. The preparation method comprises the following step: successively subjecting a solution of a crude vasopressin[4-Glu] precursor product to reversed-phase cyclization, reversed-phase purification and reversed-phase desalination by adopting a highly-efficient liquid-phase reversed-phase chromatography process, wherein a filling material for the highly-efficient liquid-phase reversed-phase chromatography process is a styrene-divinyl benzene copolymer; and the crude vasopressin[4-Glu] precursor product contains two free sulfhydryl groups. The preparation method provided by the invention innovatively adopts a reversed-phase adsorption method for cyclization, purification and desalination, solves the problems of cyclization, purification and desalination once for all, optimizes production process, and is applicable to continuous industrial production.

Spiro-thiazolones of formula Iwherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

The invention of the present application provides mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, hypertension, digestive organ disease, drug dependence, epilepsy, cerebral infarction, Therapeutic or preventive agents for diseases such as cerebral ischemia, cerebral edema, head trauma, inflammation, immune-related diseases, and alopecia. Specifically, an azole derivative represented by the general formula (I) having an arginine vasopressin 1b receptor antagonistic activity, or a pharmaceutically acceptable salt thereof is provided. 【Chemical 1】

The invention discloses a refining method of vasopressin. The refining method comprises the following steps: using high-performance liquid phase chromatography to sequentially carry out reverse-phase enrichment, reverse-phase salt conversion, and reverse-phase purification of the crude vasopressin solution , that is, the crude product solution of vasopressin is obtained by oxidizing the crude product solution of reduced vasopressin synthesized in solid phase; the filler for high performance liquid phase chromatography is a super water-resistant filler. The present invention uses the one-step method of on-line reverse-phase enrichment, reverse-phase salt conversion, and reverse-phase purification to obtain pure polypeptide products. The removal rate of impurities in crude vasopressin products is high, and the purity of pure vasopressin products is higher. The production process, in which the mobile phase in the stages of column balance, sample enrichment and salt conversion is an aqueous solution, which is environmentally friendly and pollution-free, and the effluent waste liquid can be directly treated for sewage and recycled.

The invention discloses a method for refining acetylated impurities of vasopressin. The method for refining the acetylated impurity of vasopressin comprises the following steps: the crude product solution of the acetylated impurity of vasopressin is sequentially subjected to reverse-phase enrichment, reverse-phase salt conversion, and reverse-phase purification by high-performance liquid phase chromatography; The packing of the high performance liquid reversed-phase chromatography is a super-water-resistant packing; the reverse-phase enrichment, reverse-phase salt conversion, and reverse-phase purification are all completed in a one-step reverse-phase elution process. The purification method of the vasopressin acetylation impurity of the present invention produces mostly waste water in the purification process, which can be reused after simple treatment at a sewage station, and is economical and environmentally friendly.